Author:
Bui Lynne A.,Taylor Carrie
Reference38 articles.
1. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives;Zelenetz;J Natl Compr Canc Netw,2011
2. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed September 18, 2013.
3. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development;Cai;Bioanalysis,2012
4. Follow-on biologics: challenges of the "next generation.";Schellekens;Nephrol Dial Transplant,2005
5. Biosimilars: what clinicians should know;Weise;Blood,2012
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献